PURPOSE: To evaluate the safety and efficacy of reirradiation with carbon ions in patients with relapse of skull base chordoma and chondrosarcoma. PATIENTS AND METHODS: Reirradiation with carbon ions was performed on 25 patients with locally recurrent skull base chordoma (n = 20) or chondrosarcoma (n = 5). The median time between the last radiation exposure and the reirradiation with carbon ions was 7 years. In the past, 23 patients had been irradiated once, two patients twice. Reirradiation was delivered using the active raster scanning method. The total median dose was 51.0 GyE carbon ions in a weekly regimen of five to six fractions of 3 GyE. Local progression-free survival (LPFS) was evaluated using the Kaplan-Meier method; toxicity was evaluated using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03). RESULTS: The treatment could be finished in all patients without interruption. In 80% of patients, symptom control was achieved after therapy. The 2-year-LPFS probability was 79.3%. A PTV volume of < 100 ml or a total dose of > 51 GyE was associated with a superior local control rate. The therapy was associated with low acute toxicity. One patient developed grade 2 mucositis during therapy. Furthermore, 12% of patients had tympanic effusion with mild hypacusis (grade 2), while 20% developed an asymptomatic temporal lobe reaction after treatment (grade 1). Only one patient showed a grade 3 osteoradionecrosis. CONCLUSION: Reirradiation with carbon ions is a safe and effective method in patients with relapsed chordoma and chondrosarcoma of the skull base.
PURPOSE: To evaluate the safety and efficacy of reirradiation with carbon ions in patients with relapse of skull base chordoma and chondrosarcoma. PATIENTS AND METHODS: Reirradiation with carbon ions was performed on 25 patients with locally recurrent skull base chordoma (n = 20) or chondrosarcoma (n = 5). The median time between the last radiation exposure and the reirradiation with carbon ions was 7 years. In the past, 23 patients had been irradiated once, two patients twice. Reirradiation was delivered using the active raster scanning method. The total median dose was 51.0 GyE carbon ions in a weekly regimen of five to six fractions of 3 GyE. Local progression-free survival (LPFS) was evaluated using the Kaplan-Meier method; toxicity was evaluated using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03). RESULTS: The treatment could be finished in all patients without interruption. In 80% of patients, symptom control was achieved after therapy. The 2-year-LPFS probability was 79.3%. A PTV volume of < 100 ml or a total dose of > 51 GyE was associated with a superior local control rate. The therapy was associated with low acute toxicity. One patient developed grade 2 mucositis during therapy. Furthermore, 12% of patients had tympanic effusion with mild hypacusis (grade 2), while 20% developed an asymptomatic temporal lobe reaction after treatment (grade 1). Only one patient showed a grade 3 osteoradionecrosis. CONCLUSION: Reirradiation with carbon ions is a safe and effective method in patients with relapsed chordoma and chondrosarcoma of the skull base.
Authors: Sei Young Lee; Young Chang Lim; Mee Hyun Song; Jae Yeon Seok; Won Sang Lee; Eun Chang Choi Journal: Yonsei Med J Date: 2005-04-30 Impact factor: 2.759
Authors: M M Urie; B Fullerton; H Tatsuzaki; S Birnbaum; H D Suit; K Convery; S Skates; M Goitein Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: V E M Mul; J M A de Jong; L H P Murrer; P L A van den Ende; R M A Houben; M Lacko; P Lambin; B G Baumert Journal: Strahlenther Onkol Date: 2011-12-23 Impact factor: 3.621
Authors: A Terahara; A Niemierko; M Goitein; D Finkelstein; E Hug; N Liebsch; D O'Farrell; S Lyons; J Munzenrider Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: J Debus; E B Hug; N J Liebsch; D O'Farrel; D Finkelstein; J Efird; J E Munzenrider Journal: Int J Radiat Oncol Biol Phys Date: 1997-12-01 Impact factor: 7.038
Authors: Anna V Nikoghosyan; Irini Karapanagiotou-Schenkel; Marc W Münter; Alexandra D Jensen; Stephanie E Combs; Jürgen Debus Journal: BMC Cancer Date: 2010-11-05 Impact factor: 4.430
Authors: Anna V Nikoghosyan; Geraldine Rauch; Marc W Münter; Alexandra D Jensen; Stephanie E Combs; Meinhard Kieser; Jürgen Debus Journal: BMC Cancer Date: 2010-11-05 Impact factor: 4.430
Authors: Matthias Uhl; Thomas Welzel; Alexandra Jensen; Malte Ellerbrock; Thomas Haberer; Oliver Jäkel; Klaus Herfarth; Jürgen Debus Journal: Strahlenther Onkol Date: 2015-03-04 Impact factor: 3.621
Authors: Stella K Yoo; Ben A Strickland; Gabriel Zada; Shelly X Bian; Adam Garsa; Jason C Ye; Cheng Yu; Martin H Weiss; Bozena B Wrobel; Steven Giannotta; Eric L Chang Journal: J Neurol Surg B Skull Base Date: 2020-01-14
Authors: Osama Mohamad; Brock J Sishc; Janapriya Saha; Arnold Pompos; Asal Rahimi; Michael D Story; Anthony J Davis; D W Nathan Kim Journal: Cancers (Basel) Date: 2017-06-09 Impact factor: 6.639
Authors: Sati Akbaba; Kristin Lang; Thomas Held; Olcay Cem Bulut; Matthias Mattke; Matthias Uhl; Alexandra Jensen; Peter Plinkert; Stefan Rieken; Klaus Herfarth; Juergen Debus; Sebastian Adeberg Journal: Cancers (Basel) Date: 2018-10-18 Impact factor: 6.639